UC Awarded Funding to Study Kidney Disease Treatments
Published May 2009
UC researchers have received a renewable grant from the Dialysis Corporation of America (DCA) to aid in the discovery of treatments and cures for kidney disease.
Kidney disease causes damage to the cells of the kidneys and eventually results in renal failure.
The grant, totaling $795,000 over three years, will be used to support kidney disease research by investigators in the division of nephrology and hypertension.
“We are so pleased to have formed this partnership with the Dialysis Corporation of America,” says Manoocher Soleimani, MD, professor of medicine and director of the division of nephrology in UC’s College of Medicine.
Soleimani says the grant will be used specifically for studies aimed at developing new blood and urine biomarkers for the detection and progression of kidney disease, which affects thousands of people in Greater Cincinnati.
“By uniting efforts, we can expand our activities and reach more people locally who live with kidney disease through our treatments and our ongoing research,” he continues.
“Formalizing this relationship with the University of Cincinnati allows the Dialysis Corporation of America to support kidney disease research and education in a comprehensive way while working with an organization dedicated to its mission, independence and in-tegrity,” adds DCA president and CEO Stephen Everett.
“The University of Cincinnati’s history of research and education makes this an excellent choice.”
Soleimani says this research may help doctors determine problems more efficiently and effectively—stopping other health issues from arising.
“Kidney disease is a major risk factor for the development of cardiovascular disease, thus leading to thousands of deaths per year in America,” he says.
“Developing tests that provide early detection will allow kidney specialists to initiate therapy at a much earlier time point and slow the progression of kidney disease.”